Pfizer Q3 Earnings: Revenue And Profit Beat On Heightened Demand For Paxlovid, Expects $10 Billion In 2024 Revenue From COVID Products
On Tuesday, Pfizer Inc. (NYSE:PFE) reported third-quarter adjusted EPS of $1.06, a turnaround from loss of 17 cents a year ago, beating the consensus of $0.62. The U.S. drugmaker reported sales of $17.
Pfizer Inc (PFE) reports a 32% operational revenue growth and raises full-year guidance, despite challenges in COVID-19 ...
Pfizer reported higher-than-expected profit due to strong sales of COVID-19 treatment Paxlovid. Despite this success, the ...
Pfizer beat third-quarter profit and sales forecasts and raised its guidance on strong sales of its COVID-19 treatment.
Pfizer reported an earnings beat Tuesday morning and raised its full-year outlook, seeing strength in sales of its Covid ...
Amid a looming standoff with activist investor Starboard Value, Pfizer fought back against accusations of underperforming by delivering double digit revenue growth over the third quarter and notchi | ...
Pfizer reported higher-than-expected profits driven by strong Paxlovid sales, offsetting a decline in COVID vaccine sales.
Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...
Analyst Chris Schott from J.P. Morgan maintained a Hold rating on Pfizer (PFE – Research Report) and keeping the price target at $30.00.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback